Progression-Free Survival by Prior Somatostatin Analog Use and Primary Tumor Site and Updated Safety Results in Patients with Advanced Neuroendocrine Tumors and a History of Carcinoid Syndrome: A RADIANT-2 Analysis

被引：0

作者：

Pavel, M. E. ^{[1
]}

Singh, N. ^{[2
]}

Passos, V ^{[3
]}

Strosberg, J. ^{[4
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Novartis Pharmaceut, Hyderabad, Andhra Pradesh, India

[3] Novartis Pharmaceut, Basel, Switzerland

[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

关键词：

everolimus; octreotide; mtor;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：53 / 54

页数：2